LSTA

Lisata Therapeutics, Inc.
CAPPED RATING

Lisata Therapeutics, Inc. (LSTA) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C-
Factor Score 2.1 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.1
EV / EBITDA -0.1
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M 17.4%
Price Return 12M -39.0%
Catalyst Signal 0.00
Market Cap $13.8M
TTM Revenue $100.0K
Price / Sales 138.3
ROE -101.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C- (2.1) D+ (1.7) D+ (1.8) C- (2.1) C+ (2.6) C- (2.1)
2026-11-06 B- (3.1) D+ (1.7) C- (1.9) C- (1.9) C+ (2.7) C (2.2)
2026-10-30 B- (3.0) D+ (1.6) C- (1.9) C- (2.0) C+ (2.7) C (2.2)
2026-10-23 B- (3.0) D+ (1.6) D+ (1.8) D (1.2) C+ (2.6) C- (2.1)
2026-10-16 B- (3.0) D+ (1.6) D+ (1.8) D- (0.8) C+ (2.6) C- (2.0)
Page 1 of 4